Drugs.com - New Drug Approvals

FDA Approves Miudella (copper intrauterine system) for the Prevention of Pregnancy

FDA Approves Miudella (copper intrauterine system) for ...

Feb 26, 2025 0

ROSWELL, GA, February 24, 2025 – Sebela Women’s Health Inc., a part of Sebela Ph...

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xanthomatosis

FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xa...

Feb 24, 2025 0

February 21, 2025 -- Today, the U.S. Food and Drug Administration approved Ctexl...

FDA Approves Merilog (insulin-aspart-szjj), a Biosimilar to NovoLog

FDA Approves Merilog (insulin-aspart-szjj), a Biosimila...

Feb 18, 2025 0

February 14, 2025 -- Today, the U.S. Food and Drug Administration approved Meril...

FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva

FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva

Feb 17, 2025 0

INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that t...

FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to Prolia

FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to ...

Feb 17, 2025 0

INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that t...

FDA Approves Penmenvy (meningococcal groups A, B, C, W, and Y vaccine) for Prevention of Invasive Meningococcal Disease Caused by Serogroups A, B, C, W, and Y

FDA Approves Penmenvy (meningococcal groups A, B, C, W,...

Feb 17, 2025 0

London, UK - 15 February 2025 - GSK plc (LSE/NYSE: GSK) today announced that the...

FDA Approves Vimkunya (chikungunya vaccine, recombinant) for Prevention of Disease Caused by Chikungunya Virus

FDA Approves Vimkunya (chikungunya vaccine, recombinant...

Feb 17, 2025 0

COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announc...

FDA Approves Romvimza (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor

FDA Approves Romvimza (vimseltinib) for the Treatment o...

Feb 17, 2025 0

Osaka, Japan and Waltham, Massachusetts, February 14, 2025 – Ono Pharmaceutical ...

U.S. FDA Approves Expanded Label for Astellas' Izervay (avacincaptad pegol intravitreal solution) for Geographic Atrophy

U.S. FDA Approves Expanded Label for Astellas' Izervay ...

Feb 13, 2025 0

TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President ...

$U.S. FDA Approves Pfizer’s Adcetris Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma$

U.S. FDA Approves Pfizer’s Adcetris Combination Regimen...

Feb 13, 2025 0

NEW YORK--(BUSINESS WIRE) February 12, 2025 -- Pfizer Inc. (NYSE: PFE) announced...

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

FDA Approves Genentech’s Evrysdi Tablet as First and On...

Feb 13, 2025 0

South San Francisco, CA -- February 12, 2025 -- Genentech, a member of the Roche...

FDA Approves Gomekli (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

FDA Approves Gomekli (mirdametinib) for the Treatment o...

Feb 12, 2025 0

STAMFORD, Conn., Feb. 11, 2025 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX),...

FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections

FDA Approves Emblaveo (aztreonam and avibactam) for the...

Feb 10, 2025 0

NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today anno...

FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options

FDA Approves Emblaveo (aztreonam and avibactam) for the...

Feb 10, 2025 0

NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today anno...

FDA Approves Imkeldi (imatinib) Oral Solution for the Treatment of Certain Forms of Leukemia and Other Cancers

FDA Approves Imkeldi (imatinib) Oral Solution for the T...

Feb 9, 2025 0

CAMBRIDGE, Mass.-- November 25, 2024 --Shorla Oncology (‘Shorla’), a U.S.-Irelan...

FDA Approves Rapiblyk (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting

FDA Approves Rapiblyk (landiolol) for Atrial Fibrillati...

Feb 9, 2025 0

Vienna, -- November 27th 2024 -- AOP Orphan Pharmaceuticals GmbH (AOP Health), b...

FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara

FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar ...

Feb 9, 2025 0

Bengaluru, Karnataka, India, December 01, 2024 -- Biocon Biologics Ltd (BBL), a ...

FDA Grants Accelerated Approval to Bizengri (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer

FDA Grants Accelerated Approval to Bizengri (zenocutuzu...

Feb 9, 2025 0

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) --...

Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients with Limited-Stage Small Cell Lung Cancer

Imfinzi Approved in the US as First and Only Immunother...

Feb 9, 2025 0

5 December 2024 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the U...

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatment of Cutaneous Squamous Cell Carcinoma

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatm...

Feb 9, 2025 0

WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ...

FDA Approves Crenessity (crinecerfont) for the Treatment of Children and Adults with Classic Congenital Adrenal Hyperplasia

FDA Approves Crenessity (crinecerfont) for the Treatmen...

Feb 9, 2025 0

SAN DIEGO, Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: N...

Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Galderma Receives U.S. FDA Approval for Nemluvio (nemol...

Feb 9, 2025 0

Zug, Switzerland – December 13, 2024 – Galderma today announced that the United ...

FDA Approves Vtama (tapinarof) Cream for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

FDA Approves Vtama (tapinarof) Cream for the Treatment ...

Feb 9, 2025 0

JERSEY CITY, N.J.--(BUSINESS WIRE) December 16, 2024 -- Organon (NYSE: OGN), a ...

FDA Approves Symvess (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

FDA Approves Symvess (acellular tissue engineered vesse...

Feb 9, 2025 0

DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a...

1
2
3

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.